Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...
Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...
TipRanks on MSN
Vertex Reports Strong Q3 2025 Results and Stock Buyback
( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!
The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback